Deutsch English Français

Contact

EP1058544

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1058544

EP1058544 - INHIBITION OF TNF ACTIVITY WITH COMPOSITIONS COMPRISING HEPARIN AND SOLUBLE TNF RECPETORS [Right-click to bookmark this link]
Former [2000/50]	INHIBITION OF TNF ACTIVITY
	[2004/27]
Status	No opposition filed within time limit Status updated on 30.12.2005 Database last updated on 11.09.2024
Most recent event Tooltip	25.07.2008	Change - representative	published on 27.08.2008 [2008/35]
Applicant(s)	For all designated states Applied Research Systems ARS Holding N.V. Pietermaai 15 Curaçao / AN
	[N/P]
Former [2000/50]	For all designated states Applied Research Systems ARS Holding N.V. Pietermaai 15 Curacao / AN
Inventor(s)	01 / ADERKA, Dan Rechov Meridor 15 69411 Tel Aviv / IL
	02 / ESHED (ENGLENDER), Talma Rechov Geva 6 53316 Givatayim / IL
	[2000/50]
Representative(s)	Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
	[N/P]
Former [2008/35]	Vossius & Partner Siebertstrasse 3 81675 München / DE
Former [2000/50]	VOSSIUS & PARTNER Siebertstrasse 4 81675 München / DE
Application number, filing date	99961268.2	30.12.1999
	[2000/50]
	WO1999IL00709
Priority number, date	IL19980127851	30.12.1998 Original published format: IL 12785198
	[2000/50]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO0040225
	Date:	13.07.2000
	Language:	EN
	[2000/28]
	Type:	A1 Application with search report
	No.:	EP1058544
	Date:	13.12.2000
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 13.07.2000 takes the place of the publication of the European patent application.
	[2000/50]
	Type:	B1 Patent specification
	No.:	EP1058544
	Date:	23.02.2005
	Language:	EN
	[2005/08]
Search report(s)	International search report - published on:	EP	13.07.2000
Classification	IPC:	A61K31/00, A61P43/00	[2004/27]
	CPC:	A61K31/727 (EP,US); A61K38/1793 (EP,US); A61P1/00 (EP); A61P19/02 (EP); A61P25/00 (EP); A61P29/00 (EP); (+) A61P3/10 (EP); A61P31/04 (EP); A61P31/12 (EP); A61P31/18 (EP); A61P37/00 (EP); A61P37/02 (EP); A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP); A61P9/00 (EP); A61P9/10 (EP) (-)
	C-Set:	A61K38/1793, A61K2300/00 (EP,US)
	Former IPC [2000/50]	A61K31/00
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2000/50]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
	RO	Not yet paid
	SI	Not yet paid
Title	German:	HEMMUNG DER TNF-AKTIVITÄT MIT ZUSAMMENSETZUNGEN ENTHALTEND HEPARIN UND LÖSLICHE TNF REZEPTOREN	[2004/27]
	English:	INHIBITION OF TNF ACTIVITY WITH COMPOSITIONS COMPRISING HEPARIN AND SOLUBLE TNF RECPETORS	[2004/27]
	French:	INHIBITION DE L'ACTIVITE DU TNF AVEC DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT DE L'HEPARINE ET LES RECEPTEURS SOLUBLES DU TNF	[2004/27]
	Former [2000/50]	HEMMUNG DER TNF-AKTIVITÄT
	Former [2000/50]	INHIBITION OF TNF ACTIVITY
	Former [2000/50]	INHIBITION DE L'ACTIVITE DU TNF
Entry into regional phase	29.09.2000	National basic fee paid
	29.09.2000	Designation fee(s) paid
	29.09.2000	Examination fee paid
Examination procedure	29.09.2000	Examination requested [2000/50]
	10.10.2003	Despatch of a communication from the examining division (Time limit: M04)
	19.01.2004	Reply to a communication from the examining division
	09.06.2004	Communication of intention to grant the patent
	12.10.2004	Fee for grant paid
	12.10.2004	Fee for publishing/printing paid
Opposition(s)	24.11.2005	No opposition filed within time limit [2006/07]
Fees paid	Renewal fee
	13.12.2001	Renewal fee patent year 03
	12.12.2002	Renewal fee patent year 04
	12.12.2003	Renewal fee patent year 05
	14.12.2004	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[A]EP0512528 (YEDA RES & DEV [IL]) [A] 2,3,6,7,9-11,14,15 * abstract * * page 2, line 1 - line 17 * * page 2, line 36 - line 55 * * page 3, line 3 - line 5 * * examples 1,2 * * claim - *;
		[X]WO9219249 (YEDA RES & DEV [IL], et al) [X] 1,4,5,8,10,12-14,16 * abstract * * page 6, line 32 - page 7, line 13 * * page 8, line 7 - page 9, line 28 * * page 12, line 30 - page 13, line 7 * * claims 1,2,7-13,18,20,22-24 *;
		[A]WO9406476 (IMMUNEX CORP [US]) [A] 2,3,6,7,9-11,14,15 * abstract * * page 1, line 15 - line 17 * * page 2, line 3 - line 15 * * page 3, line 12 - line 25 * * page 5, line 12 - line 13 * * page 6, line 17 - line 18 * * example 4 * * page 23, line 29 - line 36 * * claims 1-5,8,9 *;
		[A]WO9503827 (KENNEDY INST OF RHEUMATOLOGY [GB], et al) [A] 2,3,6,7,9-11,14,15 * abstract * * page 2, line 1 - line 27 * * page 4, line 28 - line 30 * * page 11, line 8 - line 17 * * examples 8,9 * * claims 13-24 * * figures 11,12 *;
		[PX]WO9909051 (ORTHOGEN GENTECHNOLOGIE GMBH [DE], et al) [PX] 8-11,14,15 * page 1, paragraph 1 * * page 3, paragraph 1 * * page 5, paragraph 2 * * page 7, paragraph 2 ** claims 1,4,8 *;
		[X] - BARAM D; RASHKOVSKY M; HERSHKOVIZ R; DRUCKER I; RESHEF T; BEN-SHITRIT S; MEKORI Y A, "Inhibitory effects of low molecular weight heparin on mediator release by mast cells: Preferential inhibition of cytokine production and mast cell-dependent cutaneous inflammation.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, (199712), vol. 110, no. 3, pages 485 - 491, XP000913798 [X] 1,4,5,8,10,12-14,16 * abstract * * page 485, column 1, paragraph 1 * * page 485, column 2, paragraph 2 - page 486, column 1, paragraph 1 * * page 487, column 1, paragraph 2 - column 2, paragraph 1 * * page 490, column 1, paragraph 3 * DOI: http://dx.doi.org/10.1046/j.1365-2249.1997.4541471.x
		[X] - IMIELA JACEK; NOSARZEWSKI JERZY; GORSKI ANDRZEJ, "Oral heparin in the treatment of rheumatoid arthritis.", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, (1995), vol. 43, no. 5-6, pages 313 - 315, XP000913796 [X] 1,8,16 * abstract * * page 313, column 1, paragraph 1 - paragraph 2 * * page 314, column 2, paragraph 2 *
		[X] - KEPROS JOHN P; WANG PING; MORRISON MARY H; CHAUDRY IRSHAD H, "Mechanism of the beneficial effects of a novel nonanticoagulant heparin (GM1892) following hemorrhagic shock: Down-regulation of proinflammatory cytokine (TNF and IL-6) production.", SURGICAL FORUM, (1995), vol. 46, pages 87 - 89, XP000913789 [X] 1,8,16 * the whole document *
		[X] - BRAZIER F; YZET T; DESSAINT C; DUCHMANN J C; PRIN L; DUPAS J L, "Effect of heparin on interleukin-6 and tumor necrosis factor alpha serum levels in inflammatory bowel diseases.", GASTROENTEROLOGY, (1996), vol. 110, no. 4 SUPPL., page A871, XP000913780 [X] 1,8,16 * the whole document *
		[X] - OLSSON I; GATANAGA T; GULLBERG U; LANTZ M; GRANGER G A, "Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy.", EUROPEAN CYTOKINE NETWORK, (1993), vol. 4, no. 3, pages 169 - 180, XP000914174 [X] 1-3,6,8-11,15,16 * abstract * * page 170, column 1, paragraph 1 * * page 171, column 2, paragraph 1 * * page 173, column 2, paragraph 4 - page 174, column 2, paragraph 2 * * figure 3 * * page 175, column 1, paragraph 2 * * page 175, column 2, paragraph 3 * * page 176, column 1, paragraph 2 * * page 177, column 2, paragraph 2 *
		[A] - ADERKA DAN, "The potential biological and clinical significance of the soluble tumor necrosis factor receptors.", CYTOKINE & GROWTH FACTOR REVIEWS, (1996), vol. 7, no. 3, pages 231 - 240, XP000913779 [A] 2,3,6,7,9-11,14,15 * abstract * * page 231, column 1, paragraph 1 * * page 231, column 2, paragraph 4 - page 232, column 1, paragraph 1 * * page 232, column 2, paragraph 5 - page 233, column 1, paragraph 1 * * page 234, column 2, paragraph 2 - page 235, column 2, paragraph 2 * * page 236, column 1, paragraph 1 - paragraph 2 * * page 236, column 2, paragraph 3 * * tables 1,2 * DOI: http://dx.doi.org/10.1016/S1359-6101(96)00026-3

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p